Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03166098 · ClinicalTrials.gov registry record
The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders
A clinical trial of Schizophrenia and Bipolar Disorder, sponsored by NYU Langone Health.
- Completed
- Registry status
- 139
- Enrollment target
- 1
- Study location
NCT03166098: Completed study of Schizophrenia and Bipolar Disorder, sponsored by NYU Langone Health.
NCT03166098 is a study of Schizophrenia and Bipolar Disorder that has completed, run by NYU Langone Health. The registered enrollment target is 139 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03166098, a study of Schizophrenia and Bipolar Disorder, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 139 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center study that uses both between-group comparisons and correlational analyses to establish biomarkers of dysmyelination and cognitive impairment in Psychotic Spectrum Disorders using imaging and neuropsychological assays.The study will provide non-invasive biomarkers of cognitive dysfunction in Psychotic Spectrum Disorder.
Primary Outcome
To compare DKI metrics (faxon, RDextra, and ADextra) in patients with SZ or BP, their unaffected siblings (SIB), and healthy comparison control (HC) subjects
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Cognitive Function Assessments
Study Locations (1)
New York
- New York University School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2016-07-05 |
| Est. Completion | 2022-03-01 |
What the finished NCT03166098 record still lists
NCT03166098 is an observational study that tracks outcomes without assigning an intervention. The registered 139 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (37% lower).
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Cognitive Function Assessments is the first listed.
NCT03166098 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03166098 about?
NCT03166098 is a clinical study titled "The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders". This is a single center study that uses both between-group comparisons and correlational analyses to establish biomarkers of dysmyelination and cognitive impairment in Psychotic Spectrum Disorders using imaging and neuropsychological assays.The study will provide non-invasive biomarkers of cognitive...
What is the current status of trial NCT03166098?
This trial is currently completed. The enrollment target is 139 participants. The study started on 2016-07-05. Estimated completion is 2022-03-01.
What conditions does trial NCT03166098 study?
This clinical trial studies the following conditions: Schizophrenia, Bipolar Disorder.
What interventions are being tested in trial NCT03166098?
The interventions under investigation include: Cognitive Function Assessments (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03166098?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03166098 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03166098's enrollment target sits among peer trials
139 114th of 315 higher than 202 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645380 · 139 participants · Phase 2
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
- NCT06239272 · 139 participants · Phase 1
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- NCT06252220 · 139 participants · Phase 1
First in Human Study in Subjects With Obesity, But Otherwise Healthy
- NCT06537128 · 139 participants · NA
Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI